Release Profile and Cytotoxicity Study of Modified Doxorubicin Nanoparticles

Abstract

Introduction: The nanoparticles can be developed into smart drug delivery systems to enhance therapeutic efficacy by manipulating the size, surface characteristics, and selective polymer material.

Objective: In the present study, we developed nanoformulations using PLGA and investigated the release profiles of encapsulated doxorubicin in different concentrations.

Methods: Fluorescence microscopy investigated cellular uptake and localization of nanoparticles in cells. MTT assay, Acridine orange/ethidium bromide (AO/EB) staining, DAPI Staining, and DCFDA staining were performed for the in-vitro anti-cancer evaluation of the synthesized nano-formulation against MCF-7 human breast cancer cell line.

Results: The results revealed that PLGA nanoparticles of Doxoribicin demonstrated an IC50 value of 0.906 µg/ml, in MCF-7 breast cancer cell line and extended-release of the drug. Conclusion: Doxorubicin can be formulated into PLGA nanoparticles for extended delivery and improved efficacy as a chemotherapeutic agent